PM54 (Zalypsis)
Multiple Myeloma
Phase 1/2Active/Recruiting
Key Facts
About Pharma Mar
Pharma Mar is a global leader in marine-based oncology drug discovery and development, leveraging its unique expertise in isolating and developing bioactive compounds from marine ecosystems. The company has successfully commercialized Yondelis® for soft tissue sarcoma and ovarian cancer, generating revenue to fund its robust clinical pipeline. Its strategic focus remains on advancing its portfolio of novel compounds, including lurbinectedin and PM54, through clinical trials for a range of difficult-to-treat cancers.
View full company profileTherapeutic Areas
Other Multiple Myeloma Drugs
| Drug | Company | Phase |
|---|---|---|
| Darzalex (daratumumab) | Johnson & Johnson | Approved |
| JNJ-4528 (CAR-T) | Johnson & Johnson | Phase 3 |
| Elrexfio | Pfizer | Approved |
| Revlimid (lenalidomide) | Bristol Myers Squibb | Commercial |
| Abecma (idecabtagene) | Bristol Myers Squibb | Commercial |
| Blenrep (belantamab mafodotin) | GSK plc | Approved |
| ABBV-383 | AbbVie | Phase 1/2 |
| REGN5458 | Regeneron Pharmaceuticals | Phase 1/2 |
| Ninlaro (ixazomib) | Takeda Pharmaceutical | Commercial |
| Tecvayli (teclistamab) | Genmab | Approved |
| Talquetamab | Genmab | Phase 3 |
| Lenalidomide (Generic Revlimid) | Dr. Reddy's Laboratories | Approved |